10x Genomics Eyes Regional Opportunities in Asia-Pacific, Launches First Overseas Manufacturing Hub

by Tyler Chen
Share To

With 25% of its global sales coming from the Asia-Pacific in the first half of 2021, 10x Genomics launched its first manufacturing facility and commercial hub in Singapore, which is also its first outside of the US.

Singapore is a global hub for biotechnology with a thriving innovation ecosystem and strong research community,” said Serge Saxonov, Co-founder and CEO of 10x Genomics. “We sincerely thank the Economic Development Board of Singapore for their incredible support and partnership and the 10x teams in Singapore and California for their tremendous efforts in bringing this site online.”


Inside the Singapore Hub

Founded in 2012, 10x Genomics is a multi-billion company with a wide range of single-cell and spatial analysis products and an R&D focus on COVID-19, cancer, neuroscience, immunology, and drug discovery. The Singapore expansion will allow the company to tap into regional opportunities in the Asia Pacific region, which include access to the Chinese market.

The hub began construction in late 2020. It now takes up 53,000 square feet in Singapore’s Solaris@Kallang 164 complex. It includes state-of-the-art, automated production suites for reagent manufacturing and a fully equipped biosafety Level-2 lab for training customers and partners on the firm’s single cell and spatial technologies.

Additionally, it has a distribution center with warehouse space and open office areas to house the current 80 employees of 10x Genomics in Singapore.


Why Pick Singapore in the First Place?

10x Genomics said they picked Singapore due to “the Singapore government’s demonstrated commitment to the biotechnology industry and business-friendly practices, world-class manufacturing expertise, and strong talent pool.” 

Singapore’s Minister of State for Trade and Industry Alvin Tan also spoke on the launch event. “Singapore is proud to be home to more than 60 multi-national MedTech companies undertaking a range of activities from manufacturing to R&D,” he said, “This best testament to what we’ve been working on, which is robust manufacturing capabilities, a thriving research base, and an innovation ecosystem, which together served as a strong proposition for MedTech companies to grow the operation here. “

The facility is expected to support and scale up 10x Genomics’s manufacturing and R&D capacity in single-cell, spatial analysis, and COVID-19 products.

© All rights reserved. Collaborate with us:
Related Post
How is China Driving Global Progress in Innovation and Access? – A Discussion with BeiGene CEO John Oyler
Singapore Will Not Cover Covid-19 Medical Bills for Those Unvaccinated by Choice
Singapore Becomes Latest Asian Country to Sign Merck Deal for Oral COVID-19 Pill
Novel RAGE Antagonist Stirs Hopes for Countering Diabetic Complications
AstraZeneca Blocks Private Equity Buyout of Swedish Pharma Sobi
Coherent Biopharma, WuXi STA Collab Takes a Crack at Peptide-Drug Conjugates
How CDMOs are Restructuring the Biopharma Landscape – An Interview with Bobby Sheng
BeiGene launches IPO on Shanghai’s STAR market to raise $3B
Novartis, UCB Take Aim at Parkinson’s Disease Under $1.65 Billion Collab
Atara Biotherapeutics’ First-In-Class Allogeneic T-Cell Therapy Accepted for EMA Review
Georgia, USA
Hong Kong, China
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!